Background: The receptor for advanced glycation end products (RAGE) modulates the
Research in Context
Evidence before this study
The acute respiratory distress syndrome (ARDS), a clinical syndrome of diffuse pulmonary oedema and inflammation, currently lacks effective therapies and is associated with high mortality and morbidity. The degrees of lung epithelial injury and of alveolar fluid clearance (AFC) impairment, as evaluated by plasma levels of soluble receptor for glycation endproducts (RAGE), are major prognostic factors in ARDS and potential therapeutic targets for ongoing research. For example, targeting RAGE with recombinant sRAGE or an anti-RAGE monoclonal antibody has proven beneficial in a translational mouse model of acid-induced ARDS.
Added value of this study
In a piglet model of acid-induced ARDS, treatment with RAGE antagonist peptide or recombinant sRAGE restored AFC and attenuated the features of lung injury, thereby confirming, in the closest evolutionary model species to humans, previous evidence from rodent models that modulation of RAGE may be a therapeutic option for ARDS. Although this is an important step towards future clinical translation, future studies should assess the best methods to modulate RAGE and further confirm the safety of manipulating this pathway in patients with ARDS.
INTRODUCTION
Acute respiratory distress syndrome (ARDS) is a frequent cause of respiratory failure and death in critically ill patients [1] . ARDS currently lacks effective therapies, although lung-protective ventilation and reasoned fluid management remain essential for better outcomes [2, 3] . ARDS is a clinical syndrome [4] characterised by diffuse alveolar epithelial and lung endothelial injury that leads to increased permeability pulmonary oedema, alveolar filling and respiratory failure [2] . The resolution of alveolar oedema and ARDS requires that the alveolar epithelial fluid transport function remain intact, which suggests that a strategy aimed at improving alveolar fluid clearance (AFC) may be beneficial for recovery from ARDS [5, 6] . The main mechanism responsible for the reabsorption of the water fraction of the oedema fluid from the airspaces of the lungs is active ion transport across the alveolar epithelium, which occurs primarily through the operation of the epithelial sodium channel (ENaC), Na,K-ATPase and aquaporin (AQP)-5 [7] .
The lung alveolar type (AT)-1 cells abundantly express the receptor for advanced glycation end-products (RAGE) as a transmembrane pattern-recognition receptor [8, 9] , suggesting that RAGE may play a central role in the pathogenesis of ARDS [8, [10] [11] [12] [13] . The activation of RAGE modulates cell signalling that leads to a sustained inflammatory response through various intracellular signalling pathways that typically lead to pro-inflammatory activation of nuclear transcription factor NF-κB and upregulation of RAGE itself [9] . Plasma levels of soluble RAGE (sRAGE) show a positive association with the extent and severity of lung injury, the degree of AFC impairment and worse clinical outcomes in ARDS [10] [11] [12] [14] [15] [16] .
Recent findings in genetically deficient (RAGE -/-) mice or rats treated with an anti-RAGE antibody suggest that targeting RAGE might be a beneficial therapy for treatment of experimental sepsis and pneumonia [17, 18] . In addition, the administration of sRAGE, which acts as a decoy receptor to prevent interactions between transmembrane RAGE and its ligands, decreased the alveolar inflammation and lung permeability in mice with lipopolysaccharide (LPS)-induced lung injury [19] . Our team recently showed that treatment with either an anti-RAGE monoclonal antibody or sRAGE attenuated lung injury, improved arterial oxygenation and decreased alveolar inflammation in a translational model of acidinjured mice [20] . The anti-RAGE therapies restored AFC and increased lung expression of 5 AQP-5 in alveolar cells, thereby providing a possible link between RAGE modulation and the mechanisms of lung epithelial injury and repair relevant to clinical ARDS [7] .
However, this type of strategy for RAGE inhibition has never been tested in a large animal model, either to determine the precise functional and biological effects of RAGE modulation in ARDS or in preparation for translation of this strategy to the clinical setting as an ARDS treatment. The aim of the present randomised trial was to investigate the potential therapeutic roles of either recombinant sRAGE or a RAGE antagonist peptide (RAP) on AFC and to establish the main features of experimental ARDS in a piglet model of hydrochloric acid (HCl)-induced ARDS. RAP is a small S100P-derived peptide with similar blocking effects to those of anti-RAGE monoclonal antibody, as it prevents RAGE from binding with several of its most important ligands, including HMGB1 and S100 proteins, in cancer cells in vitro and in vivo [21] . We also explored whether RAGE inhibition influenced lung expression of the alveolar epithelial ENaC channel, Na,K-ATPase and AQP-5.
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MATERIALS and METHODS
Animal model
Animals were maintained and all procedures were performed with the approval of the [22] .
Two-month-old white Landrace male piglets with mean (± standard deviation (SD)) weights of 10.1 (± 1.1) kg were restricted from food overnight but allowed free access to water, before receiving premedication with intramuscular azaperone (2 mg.kg -1 ). General anaesthesia was then induced with intravenous propofol (3 mg.kg [17, 20] .
Acid aspiration-induced ARDS was produced by intratracheal instillation of 0.05 M HCl, pH 1.41 (4 ml.kg -1 body weight), over 3 min at the level of the carina [24] . Based on previous studies, lung injury was considered established when the PaO2/FiO2 ratio decreased to 25% from the baseline, approximately one hour after airway HCl instillation [24, 25] .
Animals were maintained under anaesthesia and mechanical ventilation for four hours after HCl instillation. At the end of ventilation, and after arterial blood sampling and a lung bronchoalveolar lavage (BAL) with 50 mL of saline, the piglets were sacrificed with intravenous pentobarbital (150 mg.kg -1 ).
Outcome measures
Primary outcome
The primary outcome was the net AFC rate. Undiluted pulmonary oedema fluid samples were collected from the animals at baseline and four hours later, as previously described [12, [26] [27] [28] [29] [30] [31] . Briefly, a soft 14-Fr-gauge suction catheter (ConvaTec, Lejre, Denmark) was advanced into a wedged position in a distal bronchus via the endotracheal tube and oedema fluid was collected in a suction trap by applying gentle suction. All samples were centrifuged at 240 × g at 4°C for 10 min in a refrigerated centrifuge. The supernatants were collected and the total protein concentration was determined in duplicate with a colorimetric method (Pierce BCA Protein Assay Kit, ThermoFisher Scientific, Waltham, MA, USA).
Because the rate of clearance of oedema fluid from the alveolar space is much faster than the rate of protein removal [32] , the net AFC rate was calculated as Percent AFC = 100 × [1 -(initial oedema protein/final oedema total protein)] and thereafter was reported as %/h. All samples had a coefficient of variation of less than 10%. 8 
Secondary outcomes
Secondary outcomes were major criteria for experimental ARDS, as recommended by the American Thoracic Society [33] .
At baseline and every hour for four hours, arterial blood gases were measured to assess PaO2/FiO2, PaCO2, pH and serum lactate (Epoc ® Blood Analysis System, Siemens
Healthineers, Erlangen, Germany), and respiratory (tidal volume, inspiratory plateau pressure, compliance of the respiratory system, driving pressure) and hemodynamic (mean arterial pressure, cardiac index, EVLW) parameters were collected.
In addition to measuring the ELVW through transpulmonary thermodilution, the alteration of the alveolar-capillary barrier was assessed by measuring the BAL level of total protein at four hours as a surrogate for alveolar oedema. Table 1 ) [33] .
In parallel, total RNA was isolated from the lung with an RNA extraction kit (RNeasy® Mini Kit, Qiagen, Hilden, Germany). The gene expression levels of α1-ENaC (NCBI Reference Sequence, NM_213758.2), α1-Na,K-ATPase (NM_214249.1), AQP-5 (NM_001110424.1) and 36B4 (a housekeeping gene) were assessed using the quantitative real-time reverse transcription polymerase chain reaction. The aim was to explore potential mechanisms related to the lung epithelial channels involved in transepithelial fluid transport through which anti-RAGE therapies might restore AFC [20] . Threshold levels of mRNA expression (∆∆Ct) were normalised to the housekeeping gene. The values represent the mean 9 of triplicate samples ± SD and the data are representative of three independent observations. The primers are listed in Supplementary Table 2 .
The researchers performing animal experiments and collecting samples were not blinded to group allocation. However, the researchers who performed measurements from the biological samples (e.g., blood gas analyses, protein and cytokine measurement, histology score) and the statistician who performed analyses were blinded.
Statistical Analysis
All analyses were performed using Prism 6 (GraphPad Software, La Jolla, CA) or interactions and post-hoc comparisons were verified using random effects models to analyse longitudinal evolution of variables: (i) considering between-and within-subject variability (random subject effects: random intercept and slope) and (ii) evaluating fixed effects: group, time and time × group interaction. The residual normality was checked for all models. Values were log-transformed for all variables to achieve normality prior to performing random effects models.
According to the principles of the 3Rs (Replacement, Reduction and Refinement), the smallest number of animals was used (12 animals in each group) that could detect a mean difference of 5%/h (SD = 4) in the net AFC rate at four hours after lung injury (primary outcome) between HCl-injured animals and HCl-injured animals receiving sRAGE or RAP, while still considering the alpha and beta risks of 5% (bilateral) and 10%, respectively. A 10 statistical power of 90% was considered sufficient to allow multiple comparisons between groups.
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RESULTS
Alveolar Fluid Clearance
A significant between-group difference was detected in net AFC rates measured after four hours of mechanical ventilation (P = 0.02) (Fig. 1) 
Arterial Oxygenation
Two-way repeated-measurement ANOVA indicated a group effect (P = 0.001), a time effect (P = 0.03) and a significant interaction (P <10 
Alteration of the Alveolar-Capillary Barrier
A significant between-group difference was noted in BAL levels of total protein measured after four hours of mechanical ventilation (P = 10 -4 ) (Fig. 3A) . Two-way repeated-measurement ANOVA indicated a group effect (P = 0.03), a time effect (P <10 -4 ), and a significant interaction (P = 0.01) with an incremental effect of HClinduced injury on the course of EVLW, when compared with the absence of injury or with 12 the use of RAP or sRAGE (Fig. 3B) , P <10 -3 , P <0.01 and P <10 -3 , respectively). By contrast, BAL levels of cytokines were similar in the sham group and in injured animals treated with RAP or sRAGE (Fig. 4) .
Histological Evidence of Tissue Injury
Lung injury scores were higher in untreated HCl-injured animals than in sham controls or in HCl-injured animals treated with RAP or sRAGE (Fig. 5) . When compared to sham animals, alveolar wall thickening and neutrophilic alveolar-interstitial infiltrates were more evident in acid-induced than in non-injured piglets. The ARDS animals treated with RAP or sRAGE had less intense neutrophilic infiltration when compared to untreated acidinjured animals.
Other respiratory and hemodynamic variables
The values for tidal volume, PaCO2, mean arterial pressure, cardiac index and serum lactate did not differ between groups over time (Supplementary Table 3 ). However, experimental ARDS was associated with a marked decrease in the compliance of the respiratory system at 1-4 hours after injury, when compared to the baseline, the absence of injury or treatment with RAP and sRAGE. Conversely, the inspiratory plateau and driving 13 pressures were increased after acid injury at 1-4 hours after injury, when compared to the baseline, the absence of injury or treatment with RAP and sRAGE.
Lung Expression of Alveolar Epithelial Channels
Acid injury was associated with down-regulation of lung mRNA expression of epithelial channels α1-ENaC channel, α1-Na,K-ATPase and AQP-5 (Fig. 6) . Treatment with either RAP or sRAGE restored lung mRNA expression of AQP-5, whereas treatment with RAP restored lung mRNA expression of α1-Na,K-ATPase. Treatment with RAP or sRAGE had a moderate impact on lung mRNA expression of α1-ENaC that did not reached statistical significance in post-hoc, between-group analysis.
14
DISCUSSION
The main goal of this study was to determine the impact of a RAGE inhibition strategy, based either on sRAGE or RAP administration, in a piglet model of HCl-induced ARDS [12, 24] . Here, we demonstrated that both sRAGE and RAP had similar beneficial effects on the symptoms of experimental ARDS, including restoration of AFC, improvement in oxygenation, and attenuation of histological lung injury, alveolar-capillary permeability and inflammation. In addition, we proposed that RAGE inhibition might improve AFC in experimental ARDS through restored lung expression of α1-Na,K-ATPase, AQP-5 and, to a lesser extent, α1-ENaC.
Growing preclinical evidence indicates that RAGE modulation might reduce lung injury, although some uncertainty persists [34] . To date, the use of sRAGE as a decoy receptor and the use of anti-RAGE antibody as a direct antagonist have shown beneficial effects on lung injury or sepsis. Indeed, RAGE -/-mice had a survival advantage following cecal ligation puncture (CLP) when compared with wild-type mice [35] , and treatment with an anti-RAGE monoclonal antibody also decreased mortality in septic wild-type mice when compared to controls, even when treatment was administered 24 h after CLP. An anti-RAGE monoclonal antibody also improved survival in mice even when the treatment was given 6 h after intratracheal infection with Streptococcus pneumoniae [18] . An intraperitoneal sRAGE treatment reduced neutrophil infiltration, lung permeability, proinflammatory cytokine production, NF-κB activation and the number of apoptotic cells in intratracheally LPSchallenged mice [19] . However, another study showed that neither intratracheal nor intraperitoneal sRAGE treatment affected LPS-induced or Escherichia coli-induced acute pulmonary inflammation [36] . These conflicting findings on sRAGE may reflect the complexity of RAGE signalling occurring during lung injury [37, 38] . Indeed, the RAGE pathway could be considered a double-edged sword, playing important roles both in tissue injury and in resolving the pathogenesis of an offending insult [37] .
The role of the balance between RAGE circulating isoforms and ligands in the regulation of RAGE signalling remains poorly investigated under physiological conditions and in specific diseases [38] [39] [40] . For example, the use of a model of ventilator-induced lung injury (VILI) using RAGE -/-mice confirmed the contribution of RAGE activation to 15 inflammatory cell influx into the alveolar compartment, but not to other VILI parameters, such as indices of alveolar barrier dysfunction or BAL IL-6, IL-1β and keratinocyte-derived chemokine [41] . By contrast, the use of a two-hit model of VILI and inhaled LPS demonstrated that RAGE -/-mice had elevated cytokine and BAL chemokine levels and that RAGE deficiency did not affect the lung wet-to-dry ratio, total protein level or cell influx [41] . Moreover, administration of sRAGE to RAGE -/-mice attenuated the production of inflammatory mediators, probably because sRAGE can scavenge ligands that have the potential to activate other pattern-recognition receptors such as toll-like receptor 4 [42] . To our knowledge, however, our study is the first to report beneficial effects of S100P-derived RAP administration in experimental ARDS, a finding that agrees with the results from a previous study of HMGB1-derived RAP in lung-injured mice [43] .
The current study confirms our own recent results that support the benefits of using sRAGE or an anti-RAGE antibody to restore AFC and attenuate major features of lung injury in a mouse model of acid-induced ARDS [20] . Our current findings also provide further insights into mechanisms by which manipulating the RAGE pathway might counteract ARDS by AFC restoration and lung expression of lung epithelial channels α1-Na,K-ATPase, AQP-5 and, to a lesser extent, α1-ENaC. RAGE activation has been reported to stimulate ENaC activity and lung fluid clearance in uninjured mice via advanced glycation end-products [44] .
Conversely, RAGE inhibition was associated with restored AFC and lung AQP-5 expression in acid-injured mice, when compared to controls [20] . However, the precise pathways linking RAGE modulation and active transepithelial fluid transport through the regulation of epithelial barrier integrity and channel activity are not yet established.
Confirming the potential of RAGE modulation in a large animal model is a mandatory step prior to translation of ARDS treatment to the clinical setting. ARDS remains a syndrome that still lacks effective pharmacological therapies, but many issues require resolution before initiating the testing of RAGE inhibition strategies in human patients with ARDS. One issue is that RAGE inhibitors under development can take many forms, including derivatives of sRAGE that may act as decoy molecules, derivatives of RAGE ligands that block membrane RAGE, protein-protein interaction inhibitors, ligand release inhibitors and ligand inactivators [45] [46] [47] [48] . Consequently, the choice of a specific agent (or of a combination of agents) deserves full comparative investigations. A second issue is that the intact function of the RAGE pathway may be crucial for antibacterial defence, as RAGE -/-mice showed enhanced bacterial growth, increased bacterial dissemination and more severe inflammation in a model 16 of bacterial peritonitis [49] . However, contradictory findings have been published and other studies have shown that RAGE inhibition, elicited either through genetic deletion or through the use of anti-RAGE or anti-HMGB1 antibodies, was associated with unchanged or decreased bacterial dissemination [35, 50, 51] . Indeed, although trials in patients with mild
Alzheimer's disease did not support clinical efficacy of azeliragon (TTP448, vTv Therapeutics, High Point, NC, USA), an inhibitor of RAGE-amyloid β protein interactions, no obvious safety issues were associated with its use (5 mg orally once daily for 18 months)
in human patients [52] [53] [54] . Future research should therefore investigate the extent to which our current findings might translate to the treatment of critically ill patients with ARDS in terms of the timing, dosing and methods of administration of RAGE inhibition candidates, with a focus on their efficacy and safety profiles.
Our study has some limitations. One limitation is that we mainly focused on the major criteria of experimental ARDS, including AFC measurements [33] , and the assessment of animals was limited to four hours after injury. Therefore, the extrapulmonary and longer-term effects of RAGE inhibition in this model remain unknown. A second limitation is that we suggested restored AFC and lung expression of epithelial channels as potential mechanisms for the beneficial effects of RAGE inhibition, but we did not precisely characterise the specific pathways by which RAP and sRAGE might alleviate lung injury in ARDS, and this deserves further investigation. Furthermore, our findings may hold true only for acid-induced ARDS, so additional validation is warranted in other settings, such as pulmonary and extrapulmonary sepsis (the most frequent cause of ARDS), prior to considering clinical translation into more complex critical care scenarios that frequently combine multiple organ failure.
In conclusion, a RAGE inhibition strategy, using either recombinant sRAGE or RAP, The funders had no influence in the study design, conduct, and analysis or in the preparation of this article.
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